Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia

Mingqing Xu, Qinghe Xing, Sheng Li, Yonglan Zheng, Shengnan Wu, Rui Gao, Lan Yu, Tingwei Guo, Yifeng Yang, Jixia Liu, Aiping Zhang, Xinzhi Zhao, Guang He, Jian Zhou, Lei Wang, Jiekun Xuan, Jing Du, Xingwang Li, Guoyin Feng, Zhiguang Lin & 4 others Yifeng Xu, David St Clair, Zhicheng Lin, Lin He

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p= 0.00404; genotype-wise: adjusted p= 0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p= 0.0085; for haplotype C-A-C: p= 0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.

Original languageEnglish (US)
Pages (from-to)1026-1032
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume34
Issue number6
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Clozapine
Chlorpromazine
Minisatellite Repeats
Haplotypes
Schizophrenia
Nucleic Acid Regulatory Sequences
Introns
Genes
Alleles
Genotype
Gene Frequency
Antipsychotic Agents
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Antipsychotics
  • Association study
  • Chlorpromazine
  • Clozapine
  • Dopamine transporter
  • Extrapyramidal syndrome
  • Genetic polymorphism
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology
  • Medicine(all)

Cite this

Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. / Xu, Mingqing; Xing, Qinghe; Li, Sheng; Zheng, Yonglan; Wu, Shengnan; Gao, Rui; Yu, Lan; Guo, Tingwei; Yang, Yifeng; Liu, Jixia; Zhang, Aiping; Zhao, Xinzhi; He, Guang; Zhou, Jian; Wang, Lei; Xuan, Jiekun; Du, Jing; Li, Xingwang; Feng, Guoyin; Lin, Zhiguang; Xu, Yifeng; St Clair, David; Lin, Zhicheng; He, Lin.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 34, No. 6, 08.2010, p. 1026-1032.

Research output: Contribution to journalArticle

Xu, M, Xing, Q, Li, S, Zheng, Y, Wu, S, Gao, R, Yu, L, Guo, T, Yang, Y, Liu, J, Zhang, A, Zhao, X, He, G, Zhou, J, Wang, L, Xuan, J, Du, J, Li, X, Feng, G, Lin, Z, Xu, Y, St Clair, D, Lin, Z & He, L 2010, 'Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 6, pp. 1026-1032. https://doi.org/10.1016/j.pnpbp.2010.05.017
Xu, Mingqing ; Xing, Qinghe ; Li, Sheng ; Zheng, Yonglan ; Wu, Shengnan ; Gao, Rui ; Yu, Lan ; Guo, Tingwei ; Yang, Yifeng ; Liu, Jixia ; Zhang, Aiping ; Zhao, Xinzhi ; He, Guang ; Zhou, Jian ; Wang, Lei ; Xuan, Jiekun ; Du, Jing ; Li, Xingwang ; Feng, Guoyin ; Lin, Zhiguang ; Xu, Yifeng ; St Clair, David ; Lin, Zhicheng ; He, Lin. / Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010 ; Vol. 34, No. 6. pp. 1026-1032.
@article{14499a51effb47bf936b0f1f3882463f,
title = "Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia",
abstract = "A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p= 0.00404; genotype-wise: adjusted p= 0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p= 0.0085; for haplotype C-A-C: p= 0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.",
keywords = "Antipsychotics, Association study, Chlorpromazine, Clozapine, Dopamine transporter, Extrapyramidal syndrome, Genetic polymorphism, Schizophrenia",
author = "Mingqing Xu and Qinghe Xing and Sheng Li and Yonglan Zheng and Shengnan Wu and Rui Gao and Lan Yu and Tingwei Guo and Yifeng Yang and Jixia Liu and Aiping Zhang and Xinzhi Zhao and Guang He and Jian Zhou and Lei Wang and Jiekun Xuan and Jing Du and Xingwang Li and Guoyin Feng and Zhiguang Lin and Yifeng Xu and {St Clair}, David and Zhicheng Lin and Lin He",
year = "2010",
month = "8",
doi = "10.1016/j.pnpbp.2010.05.017",
language = "English (US)",
volume = "34",
pages = "1026--1032",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia

AU - Xu, Mingqing

AU - Xing, Qinghe

AU - Li, Sheng

AU - Zheng, Yonglan

AU - Wu, Shengnan

AU - Gao, Rui

AU - Yu, Lan

AU - Guo, Tingwei

AU - Yang, Yifeng

AU - Liu, Jixia

AU - Zhang, Aiping

AU - Zhao, Xinzhi

AU - He, Guang

AU - Zhou, Jian

AU - Wang, Lei

AU - Xuan, Jiekun

AU - Du, Jing

AU - Li, Xingwang

AU - Feng, Guoyin

AU - Lin, Zhiguang

AU - Xu, Yifeng

AU - St Clair, David

AU - Lin, Zhicheng

AU - He, Lin

PY - 2010/8

Y1 - 2010/8

N2 - A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p= 0.00404; genotype-wise: adjusted p= 0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p= 0.0085; for haplotype C-A-C: p= 0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.

AB - A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p= 0.00404; genotype-wise: adjusted p= 0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p= 0.0085; for haplotype C-A-C: p= 0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.

KW - Antipsychotics

KW - Association study

KW - Chlorpromazine

KW - Clozapine

KW - Dopamine transporter

KW - Extrapyramidal syndrome

KW - Genetic polymorphism

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77955057308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955057308&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2010.05.017

DO - 10.1016/j.pnpbp.2010.05.017

M3 - Article

VL - 34

SP - 1026

EP - 1032

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 6

ER -